Announcement PDF ASX ANNOUNCEMENT 22 May 2025 InvestorHub Portal and New Website to Boost Investor Engagement Melbourne, Australia; 22 May 2025: Cynata Therapeutics Limited (ASX: “CYP”, “Cynata”, or the “Company”), a clinical-stage biotechnology company specialising in cell therapeutics, has launched a new InvestorHub portal and website, for dedicated investor engagement. This will enable shareholders, stakeholders, prospective investors and partners to learn more about the Company's activities and key projects. The Company will regularly upload new content to the hub, including videos, key project news and updates. The refreshed website and associated InvestorHub can be accessed via the same web address as previously: www.cynata.com. Cynata invites shareholders and interested parties to join InvestorHub as follows: create an account on Cynata’s InvestorHub via the “sign up” button on the website, and follow the prompts. Dr Kilian Kelly, Cynata’s Chief Executive Officer and Managing Director, said: “We have a very exciting outlook ahead, especially over the next 9-12 months, as we advance towards the results of our Phase 2 and 3 clinical trials in acute graft versus host disease trial and osteoarthritis, respectively. Our new website and InvestorHub will provide a centre for our investors to stay up to date with the latest announcements. We are committed to strengthening investor engagement through our new InvestorHub, enabling direct and transparent communication. The InvestorHub platform enables our shareholders and the broader investor community to ask questions, share feedback on ASX announcements and company updates, and engage in open discussions with the Cynata team.” -ENDSAuthorised for release by Dr Kilian Kelly, CEO & Managing Director CONTACTS: Dr Kilian Kelly, CEO & MD, Cynata Therapeutics, +61 (03) 7067 6940, kilian.kelly@cynata.com Lauren Nowak, Media Contact, +61 (0)400 434 299, lauren@littlebigdeal.au About Cynata Therapeutics (ASX: CYP) Cynata Therapeutics Limited (ASX: CYP) is an Australian clinical-stage stem cell and regenerative medicine company focused on the development of therapies based on Cymerus™, a proprietary therapeutic stem cell platform technology. Cymerus™ overcomes the challenges of other production methods by using induced pluripotent stem cells (iPSCs) to achieve economic manufacture of cell therapy products, including mesenchymal stem cells (MSCs), at commercial scale without the limitation of multiple donors. Cynata has demonstrated positive safety and efficacy data for its Cymerus™ product candidates CYP-001 and CYP-006TK, in Phase 1 clinical trials in steroid-resistant acute graft versus host disease (GvHD), and diabetic foot ulcers (DFU), respectively. Further clinical trials are now ongoing: a Phase 2 trial of CYP-001 in GvHD under a cleared US FDA IND; a Phase 1/2 trial of CYP001 in patients undergoing kidney transplantation; and a Phase 3 trial of CYP-004 in osteoarthritis. In addition, Cynata has demonstrated utility of its Cymerus™ technology in preclinical models of numerous other diseases, including critical limb ischaemia, idiopathic pulmonary fibrosis, asthma, heart attack, sepsis, acute respiratory distress syndrome (ARDS) and cytokine release syndrome. Cynata Therapeutics encourages all current investors to go paperless by registering their details with the designated registry service provider, Automic Group. Cynata Therapeutics Limited ABN – 98 104 037 372 Level 3, 100 Cubitt Street Cremorne VIC 3121 Australia T: +613 7067 6940 E: info@cynata.com www.cynata.com